Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer
Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma. Read the full article: Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5) Continue this conversation on social! Follow us today ...
23 Tammi 202320min
Dan Turner on vedolizumab in children with IBD
Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD. Read the full article: Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS) Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com/thelancetgroup https://faceb...
6 Tammi 202314min
Simon Baunwall on faecal microbiota transplantation for first or second Clostridioides difficile infection
Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection. Read the full article: Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT) Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https:/...
9 Marras 202215min
James Alexander on immune responses to COVID-19 vaccination in patients with IBD
James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease. Read the full article: COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP) Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastr...
5 Loka 202213min
Filip Knop on liraglutide for bile acid diarrhoea
Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea. Read the full article: Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https:...
7 Syys 202215min
Edward Kim on radiation segmentectomy for unresectable very early to early stage hepatocellular carcinoma
Edward Kim (Icahn School of Medicine at Mount Sinai) discusses the single-arm RASER study of radiation segmentectomy for patients with unresectable very early to early stage hepatocellular carcinoma. Read the full article: Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social htt...
4 Elo 202214min
Joep Ijspeert on serrated polyp detection and risk of interval post-colonoscopy colorectal cancer
Joep Ijspeert (Amsterdam University Medical Center) discusses a population-based study exploring the detection of proximal serrated polyps and interval post-colonoscopy colorectal cancer risk. Read the full article: Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://inst...
6 Heinä 202210min
Elise Meima-van Praag on surgical closure for Crohn’s disease perianal fistulas
Elise Meima-van Praag (Amsterdam University Medical Centre) discusses the PISA-II trial, investigating short-term anti-TNF therapy with surgical closure versus anti-TNF therapy for perianal fistulas in Crohn's disease. Read the full article: Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II) Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.socia...
14 Kesä 20229min
